{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:57:10Z","timestamp":1790686630602,"version":"4.1.0"},"reference-count":27,"publisher":"Academy of Managed Care Pharmacy","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.18553\/jmcp.2026.26127","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:08:11Z","timestamp":1789139291000},"page":"1261-1270","source":"Crossref","is-referenced-by-count":0,"title":["Economic advantage of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: A cost-per-responder evaluation"],"prefix":"10.18553","volume":"32","author":[{"given":"Santosh","family":"Gautam","sequence":"first","affiliation":[{"name":"Johnson & Johnson, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Morrison","sequence":"additional","affiliation":[{"name":"Analysis Group ULC, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Thompson-Leduc","sequence":"additional","affiliation":[{"name":"Analysis Group ULC, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avani","family":"Samandur","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Menlo Park, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Macomson","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipin","family":"Khare","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yin","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Medhekar","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7818","reference":[{"key":"r1","unstructured":"Surveillance, Epidemiology, and End Results Program. Cancer stat facts: myeloma. National Cancer Institute. 2026. Accessed May 27, 2026. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"r2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"r3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422"},{"key":"r4","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad306"},{"key":"r5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203431"},{"key":"r6","doi-asserted-by":"publisher","DOI":"10.1007\/s44313-025-00102-5"},{"key":"r7","doi-asserted-by":"publisher","DOI":"10.1182\/hem.V22.1.202524"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03485-7"},{"key":"r9","unstructured":"Minimal residual disease and complete response in multiple myeloma: use as endpoints to support accelerated approval. US Food and Drug Administration. 2026. Accessed March 5, 2026. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/minimal-residual-disease-and-complete-response-multiple-myeloma-use-endpoints-support-accelerated"},{"key":"r10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014097"},{"key":"r11","unstructured":"Gerlach A. Updated IMWG guidelines spotlight MRD, functional imaging, and light chain assays in multiple myeloma.\n                      Pharmacy Times\n                      . September 17, 2025. Accessed November 19, 2025. https:\/\/www.pharmacytimes.com\/view\/updated-imwg-guidelines-spotlight-mrd-functional-imaging-and-light-chain-assays-in-multiple-myeloma"},{"key":"r12","unstructured":"FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma. US Food and Drug Administration. 2026. Accessed March 6, 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.25142"},{"key":"r14","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.42767"},{"key":"r15","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2604457"},{"key":"r16","unstructured":"ASP pricing files. US Centers for Medicare & Medicaid Services. 2025. Accessed February 13, 2025. https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files"},{"key":"r17","unstructured":"Micromedex RED BOOK. Merative. 2025. Accessed February 13, 2025. https:\/\/www.merative.com\/documents\/micromedex-red-book"},{"key":"r18","unstructured":"Hospital outpatient PPS. US Centers for Medicare & Medicaid Services. 2025. Accessed February 13, 2025. https:\/\/www.cms.gov\/medicare\/payment\/prospective-payment-systems\/hospital-outpatient"},{"key":"r19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-143234"},{"key":"r20","unstructured":"HCUPnet - hospital inpatient national statistics. Healthcare Cost and Utilization Project. 2021. Accessed February 13, 2025. https:\/\/hcup-us.ahrq.gov\/nisoverview.jsp"},{"key":"r21","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1648802"},{"key":"r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.01.011"},{"key":"r23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-144914"},{"key":"r24","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2342228"},{"key":"r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.09.003"},{"key":"r26","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70308"},{"issue":"2","key":"r27","first-page":"27","volume":"12","author":"Gupta-Werner N","year":"2025","journal-title":"J Health Econ Outcomes Res"}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:07:57Z","timestamp":1790683677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2026.26127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.18553\/jmcp.2026.26127"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2026.26127","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}